This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content

About Zinforo

About Zinforo

OverviewExtended spectrum coverage
Dosing

Dosing

Adult & adolescent dosingNeonatal & paediatric dosing
Efficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric Safety
Clinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE study
Support & Resources

Support & Resources

Videos & case studiesVideos
Materials

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo® is a fifth-generation cephalosporin with coverage against key pathogens in cSSTI and CAP1,2Increased range of activity relative to third-generation compounds2

Rapid bactericidal in vitro activity against resistant Gram-positive pathogens, including MRSA in cSSTI and penicillin-resistant Streptococcus pneumoniae in CAPˠ1–4

Clinical efficacy has been demonstrated against the following pathogens:†1

Scroll left to view table
  Gram-negative Gram-positive
Gram-negative and Gram-positive pathogens Klebsiella pneumoniae Staphylococcus aureus (MSSA only)
Haemophilius influenzae Streptococcus pneumoniaeˠ
Haemophilius parainfluenzae  
Escherichia coli
Scroll left to view table
  Gram-negative Gram-positive
Gram-negative and Gram-positive pathogens Escherichia coli Staphylococcus aureus (MRSA & MSSA)
Klebsiella pneumoniae Streptococcus pyogenes
Klebsiella oxytoca Streptococcus agalactiae
Morganella morganii Streptococcus anginosus group
Streptococcus dysgalactiae
Staphylococcus aureus and Streptococcus pneumoniae are key pathogens in cSSTI and CAP in paediatric patientsˠ5-8,11,12,14-16

S.aureus, including methicillin-resistant strains, is a major cause of cSSTI in children and adults5,6

S. pneumoniae is the most common pathogen associated with CAP in childhood.ˠ7-10 S.aureus has also emerged as a key causative pathogen.7-9

Infections caused by these pathogens are associated with increased rates of hospitalisation, complications (e.g. empyema) and mortality5,6,8,11-13

Explore more Header of this card goes here

Investigate the outcomes of the Zinforo Phase III clinical trials in adult patients with CAP and cSSTI​​​​​

Efficacy Loading

†Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1

ˠThe available clinical data cannot substantiate efficacy against penicillin non-susceptible strains of S.pneumoniae.1

There is no experience with Zinforo in the treatment of CAP in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease, those with PORT Risk Class V, and/or CAP requiring ventilation at presentation, CAP due to methicillin-resistant S. aureus or patients requiring intensive care. Caution is advised when treating such patients.1

Abbreviations

CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus.

Prescribing Information

Zinforo® (ceftaroline fosamil)

Great Britain

Zinforo 600 mg powder for concentrate for solution for infusion

Northern Ireland

Zinforo 600 mg powder for concentrate for solution for infusion

References

ZINFORO. Summary of Product CharacteristicsLaudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7Korczowski B, et al. Pediatr Infect Dis J 2016;35:e239–47Suaya JA, et al. BMC infect Dis 2014;14:296Cannavino CR, et al. Pediatr Infect Dis J 2016;35:752–59Dona D, et al. Int J Pediatr 2017; article ID 4239268Rodrigues CMC. Curr Ther Res Clin Exp 2017;84:e7–11García-Elorriaga G and Del Rey-Pineda G. J Pediatr Infect Dis 2016;1(1:3)Harris M, et al. Thorax 2011;66:ii1–23Williams DJ, et al. Pediatrics 2011;128:e479–87Moore SJ, et al. Pediatr Infect Dis J 2014;33:825–8le Roux DM and Zar HJ. Pediatr Radiol 2017;47:1392–8
Schuler CL, et al. Pediatrics 2018;137:e20181420
Ray GT, et al. BMC Infect Dis 2013;13:252
PP-ZFO-GBR-0220. September 2021
Discover specific information on the use of Zinforo in neonates, infants and children here:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​